Rocket Pharmaceuticals
RCKT
Market cap $1.51B

16.63 USD

-0.62

3.59%

At close Oct 9, 4:00 PM EDT

After hours

16.50

-0.13

0.78%

1 day

-3.59%

5 days

-0.78%

1 month

-15.71%

3 months

-21.37%

6 months

-34.40%

Year to date

-43.63%

1 year

-10.40%

5 years

50.23%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Employees: 268

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

51% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 49

3% more call options, than puts

Call options by funds: $2.46M | Put options by funds: $2.39M

1.85% less ownership

Funds ownership: 102.69% [Q1] → 100.85% (-1.85%) [Q2]

4% less funds holding

Funds holding: 183 [Q1] → 176 (-7) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

21% less capital invested

Capital invested by funds: $2.5B [Q1] → $1.97B (-$530M) [Q2]

25% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 28

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$38

129%

upside

Avg. target

$54

224%

upside

High target

$65

291%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity Whitney Ijem 40% 1-year accuracy 10 / 25 met price target	129%upside $38	Buy Maintained	30 Sept 2024
Needham Gil Blum 38% 1-year accuracy 46 / 120 met price target	213%upside $52	Buy Reiterated	17 Sept 2024
JP Morgan Eric Joseph 44% 1-year accuracy 4 / 9 met price target	225%upside $54	Overweight Maintained	6 Aug 2024
Cantor Fitzgerald Josh Schimmer 64% 1-year accuracy 38 / 59 met price target	291%upside $65	Overweight Reiterated	6 Aug 2024
Chardan Capital Geulah Livshits 19% 1-year accuracy 4 / 21 met price target	273%upside $62	Buy Maintained	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about RCKT published over the past 30 days

Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves

Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accelerated Approval for the treatment of male patients with Danon disease. The Danon disease treatment market is expected to reach $2.82 billion by 2030.

Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves

Zacks Investment Research

RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises

Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.

RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that all patients have been enrolled in the global, pivotal Phase 2 clinical trial evaluating RP-A501 to treat male patients with Danon disease. After the two-patient safety run-in, followed by harmonized global site activations, the remaining 10 patients w.

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. “As an industry-leading pharmaceutical execut.

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Zacks Investment Research

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference and the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending June 30, 2024. “Over the quarter, Rocket has been advancing its clinical pipeline as we progressed our RP-A501 and RP-A601 cardiac programs, targeting Danon disease and PKP2-ACM, and continued t.

Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

3 Biotech Names With Potential Catalysts By Year End

The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.

3 Biotech Names With Potential Catalysts By Year End

Zacks Investment Research

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.

FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment

See News Rankings

Charts implemented using Lightweight Charts™